[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
July 21, 1999

Alendronate and Fracture Prevention—Reply

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;282(3):231. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-3-jac90006

In Reply: Drs Klovning and Norheim correctly point out that results from subgroups should be regarded cautiously, especially if the results come from indiscriminate analyses of subgroups that are planned after the main results are known. This is not the case in our study. As we noted in the article, "Before unblinding, we planned to analyze the effects of alendronate on the risk of clinical fractures, vertebral fractures, and bone densities in subgroups stratified by tertile of baseline . . . femoral neck BMD." We did not plan to, and therefore we will not, analyze the data by quintiles or quartiles.

First Page Preview View Large
First page PDF preview
First page PDF preview
×